

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Ocumension Therapeutics
歐康維視生物

(Incorporated in the Cayman Islands with limited liability)
(Stock code: 1477)

CHANGE IN COMPOSITION OF THE NOMINATION COMMITTEE

The board (the “**Board**”) of directors (the “**Directors**”) of Ocumension Therapeutics (the “**Company**”) is pleased to announce that, in response to the amendments to the Corporate Governance Code as set out in Appendix C1 to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, which will become effective from July 1, 2025, Dr. Qin XIE, a non-executive Director, and Mr. Ting Yuk Anthony WU, an independent non-executive Director, have been appointed as new members of the nomination committee of the Company (the “**Nomination Committee**”) with effect from June 30, 2025.

Following this appointment, the Nomination Committee comprises three independent non-executive Directors (namely Mr. Ting Yuk Anthony WU, Mr. Yiran HUANG and Mr. Zhenyu Zhang) and two non-executive Directors (namely Dr. Lian Yong CHEN and Dr. Qin XIE), with Dr. Lian Yong CHEN remaining as the chairman.

By order of the Board
Ocumension Therapeutics
Dr. Lian Yong CHEN
Chairman and Non-executive Director

Hong Kong, June 30, 2025

As of the date of this announcement, the Board comprises Mr. Ye LIU and Dr. Zhaopeng HU as executive Directors, Dr. Lian Yong CHEN, Mr. Yanling CAO and Dr. Qin XIE as non-executive Directors, and Mr. Ting Yuk Anthony WU, Mr. Yiran HUANG and Mr. Zhenyu ZHANG as independent non-executive Directors.